Cohance Lifesciences received approval from the Ministry of Corporate Affairs for the appointment of Umang Vohra as Chairman and Group CEO. The regulatory nod was granted via a letter dated October 8, 2026, and received by the company on October 12, 2026.

This development follows earlier intimations sent to stock exchanges on April 27, 2026, and June 26, 2026, regarding the proposed leadership change. The appointment marks a significant step in the company's governance structure following its rebranding from Suven Pharmaceuticals Limited.

Regulatory timeline

The approval process involved multiple stages of disclosure and regulatory clearance. The sequence of events leading to the final confirmation is outlined below:

The appointment of Vohra, identified by DIN 02296740 in official records, consolidates the roles of Chairman and Group CEO under a single leadership figure. This dual role is common in various corporate structures but requires specific regulatory clearance when involving listed entities or specific governance norms.

Governance context

Cohance Lifesciences, formerly known as Suven Pharmaceuticals Limited, has been undergoing structural and brand transitions. The confirmation of Vohra’s appointment completes the procedural requirements set forth by the Central Government. The company secretary and compliance officer, Sisir K. Mishra, certified the receipt of the approval letter on behalf of the board.

No financial metrics or operational data were disclosed alongside this governance update. The focus remains strictly on the administrative completion of the appointment process.

Cohance Lifesciences Limited has been assigned a voluntary Environmental, Social, and Governance (ESG) rating of "Crisil ESG 61 (Strong)" by Crisil ESG Ratings & Analytics Limited.

The rating agency also assigned a Core ESG Rating of "Crisil Core ESG 67 (Strong)" to the pharmaceutical company. This assessment was disclosed to stock exchanges on October 6, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Independent Assessment Process

Cohance clarified that it did not engage Crisil ESG Ratings for this evaluation. The rating was independently determined by the agency based on publicly available information pertaining to the company. This distinction highlights that the score reflects an external analysis of public disclosures rather than a commissioned audit or internal review process initiated by the firm.

Rating Details

The disclosure references SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, regarding the reporting of such ratings. The company, formerly known as Suven Pharmaceuticals Limited, maintains its corporate office in Hyderabad and registered office in Mumbai.